The Medicines Company: Cowen and Company Annual Health Care Conference (The Medicines Company) - Mar 6, 2015 - “MDCO-216 Phase I clinical data”; “A single infusion of MDCO-216 modulated lipid parameters profoundly increased ABCA1 mediated cholesterol efflux and was well tolerated”; “These single dose data are consistent with the lipid profile of carriers of the ApoA1-Milano variant3 and data seen in monkeys in a previous study with MDCO-216”; “These data support further development of this agent as a disease-modifying treatment for reducing atherosclerotic disease and subsequent cardiovascular events”
P1 data • Dyslipidemia
|